DexCom (DXCM) just received FDA clearance for Smart Basal, a new device designed to help adults with Type 2 diabetes optimize their insulin dosing using personalized, real-time sensor data. This ...
Tuesday, the FDA approved DexCom Inc’s (NASDAQ:DXCM) Stelo Glucose Biosensor System as the first over-the-counter (OTC) continuous glucose monitor (CGM). The Dexcom Stelo Glucose Biosensor System is ...
DexCom DXCM recently announced that it has received FDA clearance for its CGM-integrated basal insulin dosing optimizer, Dexcom Smart Basal, for use by adults with Type 2 diabetes on glargine U-100 ...
DexCom, Inc. DXCM recently received the FDA’s Breakthrough Device Designation for the Dexcom continuous glucose monitoring (“CGM”) system’s use in the hospital setting. The designation is expected to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback